MET and neoplasm: The combination of EGFR-TKI and selective MET-TKI had shown promising clinical efficacy and safety in the early phase of clinical trials.17, 18, 19 MET positivity for inclusion of patients in these clinical trials was determined by either FISH alone (MET/centromere of chromosome 7 ratio of ≥2 or MET gene CN ≥5),19 the combination of IHC (MET 2+/3+) and FISH,17 or the combination of IHC (MET 3+ expression in ≥50% of tumor cells), FISH, and NGS (≥5 copies of MET).18